S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17

Ironwood Pharmaceuticals (IRWD) Stock Forecast, Price & News

+0.13 (+1.13%)
(As of 05/17/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
2.20 million shs
Average Volume
2.50 million shs
Market Capitalization
$1.79 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive IRWD News and Ratings via Email

Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Ironwood Pharmaceuticals logo

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$413.75 million
Cash Flow
$1.20 per share
Book Value
$3.74 per share


Net Income
$528.45 million
Pretax Margin




Free Float
Market Cap
$1.79 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.42 out of 5 stars

Medical Sector

188th out of 1,426 stocks

Pharmaceutical Preparations Industry

74th out of 680 stocks

Analyst Opinion: 3.3Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 3.1 5 -4 -3 -2 -1 -

Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions

Is Ironwood Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ironwood Pharmaceuticals stock.
View analyst ratings for Ironwood Pharmaceuticals
or view top-rated stocks.

When is Ironwood Pharmaceuticals' next earnings date?

Ironwood Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Ironwood Pharmaceuticals

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its quarterly earnings results on Thursday, May, 5th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by $0.10. The biotechnology company had revenue of $97.53 million for the quarter, compared to the consensus estimate of $96.62 million. Ironwood Pharmaceuticals had a net margin of 124.83% and a trailing twelve-month return on equity of 33.93%. The company's revenue was up 9.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.24 EPS.
View Ironwood Pharmaceuticals' earnings history

What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?

Ironwood Pharmaceuticals issued an update on its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $420.00 million-$430.00 million, compared to the consensus revenue estimate of $429.48 million.

What price target have analysts set for IRWD?

3 brokerages have issued 1 year target prices for Ironwood Pharmaceuticals' stock. Their forecasts range from $14.00 to $16.00. On average, they anticipate Ironwood Pharmaceuticals' stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 28.8% from the stock's current price.
View analysts' price targets for Ironwood Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Ironwood Pharmaceuticals' key executives?
Ironwood Pharmaceuticals' management team includes the following people:
What is Mark Mallon's approval rating as Ironwood Pharmaceuticals' CEO?

7 employees have rated Ironwood Pharmaceuticals CEO Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among Ironwood Pharmaceuticals' employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Who are Ironwood Pharmaceuticals' major shareholders?

Ironwood Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.13%), Vanguard Group Inc. (8.39%), State Street Corp (5.21%), LSV Asset Management (4.65%), Renaissance Technologies LLC (1.96%) and Dimensional Fund Advisors LP (1.93%). Company insiders that own Ironwood Pharmaceuticals stock include Alexander J Denner, Jason Rickard, Julie Mchugh, Kelly Macdonald, Mark G Currie, Michael Shetzline, Ronald Silver, Thomas A Mccourt and Timothy M O'reilly.
View institutional ownership trends for Ironwood Pharmaceuticals

Which institutional investors are selling Ironwood Pharmaceuticals stock?

IRWD stock was sold by a variety of institutional investors in the last quarter, including Foundry Partners LLC, Prudential Financial Inc., Federated Hermes Inc., AlphaCrest Capital Management LLC, State Board of Administration of Florida Retirement System, Great Lakes Advisors LLC, Skandinaviska Enskilda Banken AB publ , and Vanguard Group Inc.. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Jason Rickard, Julie Mchugh, Mark G Currie, Michael Shetzline, Ronald Silver, and Thomas A Mccourt.
View insider buying and selling activity for Ironwood Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Ironwood Pharmaceuticals stock?

IRWD stock was acquired by a variety of institutional investors in the last quarter, including Royce & Associates LP, Renaissance Technologies LLC, State Street Corp, SG Americas Securities LLC, State of New Jersey Common Pension Fund D, First Trust Advisors LP, BlackRock Inc., and Healthcare of Ontario Pension Plan Trust Fund. Company insiders that have bought Ironwood Pharmaceuticals stock in the last two years include Alexander J Denner, and Timothy M O'reilly.
View insider buying and selling activity for Ironwood Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ironwood Pharmaceuticals' stock price today?

One share of IRWD stock can currently be purchased for approximately $11.65.

How much money does Ironwood Pharmaceuticals make?

Ironwood Pharmaceuticals has a market capitalization of $1.79 billion and generates $413.75 million in revenue each year. The biotechnology company earns $528.45 million in net income (profit) each year or $3.19 on an earnings per share basis.

How many employees does Ironwood Pharmaceuticals have?

Ironwood Pharmaceuticals employs 219 workers across the globe.

What is Ironwood Pharmaceuticals' official website?

The official website for Ironwood Pharmaceuticals is www.ironwoodpharma.com.

How can I contact Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The biotechnology company can be reached via phone at (617) 621-7722, via email at [email protected], or via fax at 617-494-0480.

This page was last updated on 5/18/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.